

PATENT APPLICATION
File No: 98-75C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Jane A. Gross, Wenfeng Xu, Karen Madden, David P. Yee
Serial No. : 09/627,206
Group Art Unit : 1645
Examiner : Zemian, R.
Filed : July 27, 2000
For : SOLUBLE RECEPTOR BR43X2 AND METHODS OF USING
Date Submitted : January 31, 2002

RECEIVED
FEB 25 2002
TECH CENTER 1600/2900

AMENDMENT FEE TRANSMITTAL

BOX NON-FEE AMENDMENT
Commissioner for Patents
Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-mentioned application.
The fee required to be filed with the accompanying amendment has been calculated as shown below:


CLAIMS AS AMENDED

	Claims Remaining After Amendment	Highest No. Covered by Previous Payments	Present Extra	Extra Rate	Fee
Total	28	-88	0	\$9.00	\$000.00
Independent	1	- 7	0	\$42.00	\$000.00
1st Presentation of Multiple Dependent Claim				\$140.00	\$000.00
Total					\$000.00

Applicants claim small entity status. Please charge any required fee to
ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Phillip B.C. Jones, J.D., Ph.D.
Registration No. 38,195



PATENT APPLICATION
File No.: 98-75C2

Amt
8/A

hinda

2/28/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB. 25. 2002

TECH CENTER 1600/2900

In re Application of: Jane A Gross *et al.*

Serial No.: 09/627,206

Group Art Unit: 1645

Filed: July 27, 2000

Examiner: Robert A. Zeman

For: Soluble Receptor BR43X2 and Methods of Using

PRELIMINARY AMENDMENT

Commissioner of Patents
Washington, DC 20231

Sir:

Please amend the above-identified patent application as follows.

In the Application:

Please delete the following inventors from the above-identified patent application:
Wenfeng Xu, Karen Madden, and David P. Yee.

In the Specification:

Please replace the title at page 1, line 6, with the following rewritten title:

a --METHODS FOR INHIBITING B LYMPHOCYTE PROLIFERATION WITH
SOLUBLE ZTNF4 RECEPTORS--

In the Claims:

Please cancel claims 1 to 88 without prejudice or disclaimer to the subject matter therein.